Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors
Authors:
- Jianwei YanJYJianwei Yan
- Ning HuangNHNing Huang
- Shukun LiSLShukun Li
- Liu-Meng YangLYLiu-Meng Yang
- Weiqiang XingWXWeiqiang Xing
- Yong-Tang ZhengYZYong-Tang Zheng
- Youhong HuYHYouhong Hu
- 1 March 2012
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (5) , 1976-1979
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (30600775, 81001462)
- Eleventh Five-Year Key Scientific and Technological Program of China (2009ZX09501-029)
- CAS Knowledge Innovation Project (KSCX2-YW-R-185)
This publication has 27 references indexed in Scilit:
- Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapineAIDS, 1999
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998
- Resistance to Human Immunodeficiency Virus Type 1 Protease InhibitorsAntimicrobial Agents and Chemotherapy, 1998
- Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patientsAIDS, 1998
- A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitorsAIDS, 1998
- Indinavir-associated lipodystrophyAIDS, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Visceral abdominal-fat accumulation associated with use of indinavirThe Lancet, 1998
- “Buffalo hump” in men with HIV-1 infectionThe Lancet, 1998
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995